Mylan comments on generic Advair Diskus abbreviated new drug application. Mylan N.V. commented on the status of its abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s Advair Diskus. In conjunction with Mylan’s GDUFA goal date, the company received a complete response letter from FDA regarding…